Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bempedoic Acid vs Nilemdo in Healthy Adults
NCT07170852Phase 1Completed
- Sponsor
- Humanis
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bempedoic acid in hypercholesterolemia (2 arms), sponsored by Humanis. Primary endpoints: Maximum measured plasma concentration at 72 hours and Area under the plasma concentration versus time curve from zero to last quantifiable concentration at 72 hours. Started May 2025; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07170852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170852.